2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

MANAGEMENT OF T1 BREAST CANCERS
Table 1. T1ab N0 Breast Cancer Literature Review (Papers Published 2002–2011) (Cont’d)
Time %DFS %RFS
Measure of Efficacy
%DDFS %OS %IBTR Adverse Factors Comments HER2 Test
8y �71% T1b HER2 unk
81.6 96.7 94 90.7 IBTR: HR 0.19 for XRT;
84.4 98.5 93.4 97.8
HR 0.37 for Tam
77.8 96.8 94 83.5
7 y 98.7 HER2 unk
4.2 y size, HER2�, Ki67 � 49 T1a 100% DFS IHC 3� 10%
93
100
20%, G � 1
or CISH
DFS: high nuclear IBTR: nuclear grade, HER2 unk
grade, non-tubular DCIS present
60.6 82.1 89.2 OS: LVI
56 77.8 89.8
61.5 82.2 80.5
10 y 66 versus
76 HER2
71 versus
82 HER2
IHC 3� 10%
or FISH
�94 T1b a bit worse SP3 Ab
�85
5 y 92 96 HER2�, ER-, age
� 50, high grade
ER-5y RFS 83.3% IHC 3� 10%
or FISH
94 97 HER2-
77 (HR 2.7) 86 (HR 5.3) HER2�
HR 3.9 HR 2.8 TN
96 5y RFS TN 95% (n � 125);
no diff T1a versus T1b
IHC 3� 10%
or FISH
97 HER2-
87 HER2�
5 y 91.5 96.3 94.6 Age � 35, HER2� worse Fig 1 IHC 3� 10%
94.5 97.5 than TN
excluded CT and trastuzumab or FISH
77.2 (HR 4.98) 86.9 (HR 4.7)
84.9 (HR 2.71) 96.3 (HR 2.1)
more T1a
Age � 35, HER2� then
TN, LVI
ER/PR at 1% threshold;
Ki67 14%
5 y BCS �98 Fig 1
�97
�95
�91 Tmic overrepresented (27%)
�91
5 y 97 HER2�, ER-, � 50 y,
no adj therapy, G3
95
74
IHC 3� 10%
T1a more HER2�, ER- IHC 3� or DISH
50% HER� also ER�
TN 5 y DFS 91%
5 y 96.5 93.7 1 age � 50; ER-, HER2� HR 3.66 for HER2� DFS IHC 10% 3�
92 90.3 1 63% T1b
or FISH
91.8 1
4y Ki67 � 20% HR 12.9; 76% T1b; more G3 in IHC 3� 10%
6 events
3 events
� 35, PR-
T1mic, no events in T1mic
10 y HR 1.02 for
BCSM: � 50, G3, �4% died of BC;
HER2 unk
1 mm T size
ER-, PR-, � 6LN in
ALND; OS: � 50,
AA, T1b, PR-
24% all-cause
5 y HR 2.4 IHC 3� 10%
92 (HR 5.2) HR 5.1 for HER2� T1a DFS 88%; T1b 95% or FISH
99 T1a 97%; T1b 99%
91 T1b, multifocal T1a 93%; T1b 85%
92 T1a 87%; T1b 94%
13